Hugel Recruits Brent Saunders, Former Allergan Chairman, a Global Giant in Medical Aesthetics

Brent Saunders.

[Asia Economy Reporter Lee Gwan-joo] Hugel announced on the 20th that it will convene an extraordinary general meeting of shareholders to appoint Brent L. Saunders, former CEO and chairman of Allergan (currently AbbVie), as a director.

Hugel plans to appoint former Chairman Saunders as a non-executive director at the extraordinary general meeting on the 29th of next month, and then elect him as chairman of the board to lead Hugel's board of directors.

Former Chairman Saunders is an expert with 25 years of experience in the pharmaceutical, bio, and healthcare industries, having held key executive positions at leading global companies. Notably, from 2015 to 2020, he served as CEO and chairman of Allergan, leading the portfolio including the botulinum toxin product 'Botox' and the filler brand 'Juvederm,' and is well known for successfully completing the $63 billion merger and acquisition (M&A) with AbbVie.

In addition to Allergan, he has held positions such as President of Schering-Plough's Global Consumer Division, Chairman and CEO of Bausch & Lomb, Chairman of Forest Laboratories, and currently serves as CEO of VesperHealth, accumulating extensive experience in the global pharmaceutical and medical aesthetics industries.

Former Chairman Saunders expressed, “I am pleased to join the world-class team of Hugel, CBC, and GS to accelerate growth as a global leader in medical aesthetics,” adding, “I look forward to Hugel’s future, which is committed to excellent quality, customer-focused sales and marketing, and continuous research and development (R&D).”

Hugel plans to accelerate its global market expansion by bringing former Chairman Saunders onto the board. A Hugel representative stated, “Brent Saunders is known for leading outstanding achievements in the global medical aesthetics industry,” and added, “Brent Saunders’ expertise and global experience will be a great support for Hugel’s efforts to leap into the global market.”

Meanwhile, Hugel’s largest shareholder recently changed to Aphrodite Acquisition Holdings LLC. Aphrodite is a multinational consortium composed of GS Group, Singapore-based global healthcare investment fund CBC Group, domestic private equity firm IMM Investment, and the Middle Eastern sovereign wealth fund Mubadala’s investment company.

This content was produced with the assistance of AI translation services.